MADRIGAL PHARMACEUTICALS INC. overview

Thinking about trading options or stock in Palantir Technologies, Symbotic, Super Micro Computer, Madrigal Pharmaceuticals, or Futu Holdings? PR Newswire NEW YORK, Feb. 6, 2024 NEW YORK , Feb. 6, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, SYM, SMCI, MDGL, and FUTU. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The...

- Successfully Completed Merger and Transition to Public Company - - Initiated Phase II study in NASH - - Out-licensed non-core asset HSP90 to Tarveda Therapeutics - WEST CONSHOHOCKEN, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today reported financial results for the third quarter ended September 30, 2016. For the three months ended September 30, 2016, the company reported a net loss of $14.0 million or $1.34 per share. This compares to a net loss of...

-- Study expected to provide proof-of-concept data in NASH for the first liver-directed, thyroid hormone receptor (THR) ß-selective agonist – -- Primary endpoint is the reduction of liver fat, assessed by MRI-PDFF, at 12 weeks, with confirmation of NASH resolution by biopsy at 36 weeks -- CONSHOHOCKEN, Pa., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of...